spyglass_IOL_eluting.jpg

Intraocular Drug Delivery THAT LASTS

The first and only controlled release drug delivery platform for all cataract surgeons

HOW IT WORKS

The SpyGlass Drug Delivery Platform is implanted with the SpyGlass IOL into the capsular bag via standard cataract surgical technique

The SpyGlass Drug Delivery Platform has not been approved by the FDA for any use

The SpyGlass drug delivery platform consists of a single-piece, hydrophobic acrylic IOL and two drug eluting pads that slide over each haptic and securely attach at the haptic junction. With the drug pads securely attached, the IOL and pads are loaded into a standard IOL injector. The lens is advanced and injected through a sub 2.4 mm incision and implanted directly into the capsular bag. 

The drug pads remain outside the visual axis and continuously elutes directly into the aqueous humor which carries the active drug to the target tissue. 

A VERSATILE SYSTEM

The SpyGlass Platform combines the heritage and performance of a single-piece IOL and the ability to secure innovative, drug-eluting pads to the haptics of the IOL prior to loading and implantation

Beyond bimatoprost, the SpyGlass drug-eluting pads are uniquely designed to deliver additional drugs to address multiple ophthalmic indications 

The SpyGlass Drug Delivery Platform has not been approved by the FDA for any use

IOL_pads_outline.jpg

CONSISTENT DAILY RELEASE

DESIGNED FOR CONSISTENT DAILY RELEASE

Targeting three years of bimatoprost sustained delivery for glaucoma management

daily_release.jpg

The SpyGlass Drug Delivery Platform has not been approved by the FDA for any use

PRECLINICAL TESTING

Compelling IOP lowering in normotensive beagles

  • 3 doses compared to 0.03% topical bimatoprost

  • Normalized out the IOP reduction from cataract surgery alone

Clear indication of safety in NZW rabbits

  • No detectable systemic exposure

  • No drug related AEs even at 10x max dose up to 9 months

FIH FEASIBILITY STUDY

A prospective study outside of the US to evaluate the safety and efficacy of the sustained release bimatoprost implant with SpyGlass IOL in patients with ocular hypertension or mild to moderate open-angle glaucoma

spyglass_FIH_study.jpg

The SpyGlass Drug Delivery Platform has not been approved by FDA for any use

FIH Feasibility Study

Screen Shot 2022-10-25 at 1.31.38 PM.png

​Results at 3 Months

  • 45% mean IOP reduction across all doses
     

  • 100% of patients ≤ 18 mmHg
     

  • All patients off topical IOP-lowering therapy

texture_bg.jpg

SpyGlass Pharma innovative drug delivery platform presentation at AAO 2022 (Credit: Eyecelerator)